Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming when stakes are high
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
December 11, 2025
Cell and Gene Therapy Video Recap—December 11, 2025
December 11, 2025
Cell and Gene Therapy Today—December 11, 2025
December 11, 2025
Rare Disease Today—December 10, 2025
December 11, 2025
Cardiovascular Today—December 10, 2025
December 11, 2025
Lucid Diligence Brief: EpilepsyGTx $33m Series A
December 10, 2025
Immunology Today—December 10, 2025
December 10, 2025
Women’s Health Video Recap—December 10, 2025
December 10, 2025
Neuroscience Video Recap—December 10, 2025
December 10, 2025
Neuroscience Today — December 10, 2025
December 10, 2025
Lucid Diligence Brief: SanegeneBio RNAi $110 million Series B
December 9, 2025
ESMO Immuno-Oncology 2025 Preview: Key Highlights to Watch
December 9, 2025